Axovant | search
Click here to view Axovant news from 60+ newspapers.
Bookmark or Share- Sio Gene Therapies to dissolve after years of setbacksThe company rebranded as Axovant Gene Therapies in 2019 and spun out its small molecule research into a company called Arvelle Therapeutics. Shares in the company sank again in 2020 after it ran into manufacturing issues for an experimental Parkinson’s drug.
- Axovant Gene Therapies Announces Name Change to Sio Gene TherapiesNEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases,...
- Sio Gene Therapies - WikipediaSio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland.
- Axovant Gene Therapies Announces Name Change to Sio Gene - GlobeNewswireNEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases,...
- FDA clears IND application for Tay-Sachs gene therapyThe Axovant therapy, AXO-AAV-GM2, is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff. The clinical hold was in place to resolve two outstanding questions regarding product drug characterization.
More
